Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 5,450 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more
Conditions
Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms
Interventions
HKI-272, Paclitaxel
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
8
States / cities
La Jolla, California • San Diego, California • Boston, Massachusetts + 4 more
Completed Phase 1Phase 2 Interventional Results available

Study of BMS-986158 in Subjects With Select Advanced Cancers

NCT02419417
Conditions
Advanced Tumors
Interventions
BMS-986158, Nivolumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Conditions
Solid Tumors
Interventions
STA 9090 (ganetespib)
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
25 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan
Completed No phase listed Observational

The Good Patient Study

NCT02199548
Conditions
Solid Tumor, Hematological Malignancies, Brain Tumor
Interventions
Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 19 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Memphis, Tennessee
Conditions
Advanced Solid Tumors
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Fort Wayne, Indiana • Detroit, Michigan • Farmington Hills, Michigan + 2 more
Conditions
Solid Tumor
Interventions
Decitabine, Cedazuridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm
Interventions
adagrasib (MRTX849)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
San Francisco, California • Santa Rosa, California • Hartford, Connecticut + 8 more
Conditions
Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Multiple Myeloma, Lymphoma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
7
States / cities
Scottsdale, Arizona • Beverly Hills, California • Chicago, Illinois + 4 more
Conditions
Neoplasm Metastasis
Interventions
Gebasaxturev, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hackensack, New Jersey • Portland, Oregon
Withdrawn Not applicable Interventional Accepts healthy volunteers

Wet Heparinized Suction for Abdominal Cancer

NCT05041335
Conditions
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Interventions
wet heparinzed suction, Microsieve, No heparin flush, No microsieve
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Neratinib Maleate, Palbociclib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
193
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 154 more
Conditions
Adult Solid Neoplasm
Interventions
Belinostat, Isotretinoin, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 2 more
Conditions
Metastatic Solid Tumors
Interventions
PZP115891, PCI-24781
Drug
Lead sponsor
Pamela Munster
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions
Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
212
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, dexamethasone, ketoconazole
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Cancer, Tumor
Interventions
Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Cancer
Interventions
PQR 309
Drug
Lead sponsor
PIQUR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Solid Tumors
Interventions
ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Conditions
Solid Tumor
Interventions
Oraxol
Drug
Lead sponsor
Kinex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Aurora, Colorado • Baltimore, Maryland • Buffalo, New York
Conditions
Solid Tumors, Cancer
Interventions
Oral DFP-11207
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Cancer
Interventions
CDX-0158 (formerly known as KTN-0158)
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Nashville, Tennessee
Conditions
Solid Tumors
Interventions
BKM120 days 1 - 21 plus paclitaxel + carboplatin, BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin, BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1), BKM120, Paclitaxel + Carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumours
Interventions
AZD4956, Saruparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New York, New York • Providence, Rhode Island • Houston, Texas + 1 more